Some good and bad news today:
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint —
— Overall survival, the other primary endpoint, was not statistically significant —
— Safety findings consistent with fruquintinib known profile —
What's the betting that the bad will outweigh the good? I hope I am pleasantly surprised by the reaction!
PS - Good start in HK = +4% |
yes I agree, geo-politics combined with the company's amazing ability to inflict self-harm has now made this uninvestable. There is no point me selling now and I suspect many others are in the same position, but equally, there seems little point in anyone buying either. |
Yes, seems an interesting share, down 10% or so today, not sure why as yet.... |
nothing seems to make a difference bad news and this gets absolutely hammered, anything positive and it makes no difference.... |
Good to see them ascribe a value of 531p a share. Quite a gap to close. |
Trinity Delta has just published a new research note |
In a statement to The Wall Street Journal on Tuesday, the CSRC said: "China and the U.S. main-tain close communications and are committed to reaching collaborative arrangements that comply with both countries' laws and regulations. Overall, the negotiation process is going smoothly."WSJ 25 AugLight at the end of tunnel for the "listings" furore?Alibaba etc up 10% + on Nasdaq. |
Prob working for Beigene…. |
I wonder what their sizeable U.S. Sales Team are currently doing with themselves or have they been laid off? |
The Pipeline may be progressing but there is a three year delay on Surufatinib global sales which with an industry gross margin of 80% is not to be sniffed at. The lost margin and the cost of the New phase three study could be in the region of $100-200m
Losses this year of $350m are likely and a substantial loss is baked in for 2023.
The CFO suggested they have funding for three years and are carefully allocating funds.
They need to avoid a fund raising that will be dilutive to existing shareholders, with fruquintinib not marketed outside China until 2024 it will be touch and go whether they can get far into 2024 without a capital raise or sale of their other interests.
The best thing for existing shareholders would be a merger of equals with a company with overlapping products so that the lower performing programs can be cut and cash preserved. |
Indeed.We seem to be on the frontline of what is a mini geopolitical stand off.Hutchmed,along with some other Chinese Nasdaq listed companies,seem unwilling (if not unprepared)to give a commitment to fulfil SEC requirements.The fungible aspect of holding HK/AIM in place of US listed stock is a thorny issue for most North American institutions i suspect.Anyway,has Hutchmed made itself such an attractive proposition that one would be prepared to jump through a series of irritating hoops to sustain a holding.You probably won't want to add until things re listing are clarified.That apart and ignoring ethnicity screw ups on data submission,the company seems to be making real progress albeit the progress won't be reflected in the share price! |
So all systems go for the de-listing still. Little to no hope of the company ever seeing a sensible valuation then. |
timberr... |
What will happen if they ever deliver a bad RNS ? |
Volume in HK was 6.5 million as opposed the 2 million average. Maybe someone has got win of EMA approval for Surufatinib... or maybe we will see a stock market notification shortly regarding a big purchaser |
Any idea on today’s big tick up. Generic China bounce or company specific |
So far so good. |
bottom,big shareholders are reducing their short positions and buying more stock |
Is this the bottom, or will there be another leg down? |
thanks Gents, or ladies...... |
Lomcovaks. Let's hope so. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
